Latest News
-
Philanthropic funds launch crucial research into little-known cancer
Posted on:
Generous community support is strengthening our research into oesophageal cancer, lifting hopes of improved treatments for the aggressive and deadly cancer. The Fight for a Cure charity has donated $100,000 towards Dr Colby Stevenson’s research, on top of a $100,000 donation from the Howlett family, in memory of their son Scott who died from the
Category:
-
Leading new centre to strengthen cancer research and expertise
Posted on:
Researchers at the Kolling Institute have welcomed the launch of Australia’s premier cancer clinical trials centre on the Royal North Shore Hospital campus. NORTH Sydney Trials and Research Van Norton Poche or NORTH STAR VNP has been made possible by a $20 million gift from the late Kay Van Norton Poche and her husband Greg.
Category:
-
Crucial steps towards gene therapy for debilitating Meniere’s disease
Posted on:
Our researchers at the Kolling Institute are at the forefront of Meniere’s disease science developing the first humanised model of the disease ahead of gene therapy. The specialised team is led by world-leading Meniere’s disease researcher and neuroscientist Professor Jose Antonio Lopez-Escamez who relocated from Spain to the institute to pursue his ground-breaking work. His
-
Researchers develop urine test based on kidney cell colour and AI to diagnose chronic kidney disease
Posted on:
We may soon have a convenient and painless approach to diagnose chronic kidney disease following research by the team from the Kolling Institute’s Renal Research Laboratory. Chronic kidney disease is an emerging global health issue, currently affecting more than 11 per cent of Australians and 13 per cent of the worldwide population. By 2032, it’s
-
Special Research Feature – Year in Review 2023
Posted on:
Our Kolling Institute Year in Review profiles our innovative and life-changing research across the Kolling Institute. Our researchers are driving investigations into some of the most challenging health conditions from heart and kidney disease to musculoskeletal conditions, chronic pain, cancer and neurodegenerative disorders. Our teams have continued to increase their research impact, while forging significant new collaborations. They
-
Valuable new funds support game-changing cancer research
Posted on:
Our ground-breaking leukaemia research at the Kolling Institute has received an important boost with the Cancer Council NSW announcing a $450,000 grant for Associate Professor Jenny Wang and her research team. The funds will help the development of a new therapy to greatly improve survival rates for those with acute myeloid leukaemia. This form of
Category:
-
World first research to develop cognitive impairment guidelines after spinal cord injury
Posted on:
A team of researchers from the Kolling Institute’s John Walsh Centre for Rehabilitation Research has launched a study to develop the first internationally accepted guidelines for assessing cognitive function after a spinal cord injury. The latest data indicates that over 15 million people globally live with a spinal cord injury, and in Australia, there are
-
Innovative musculoskeletal program heads to the bush
Posted on:
In a sign of the strength of the Kolling Institute’s research and clinical capabilities, Professor Trudy Rebbeck has been awarded a $2.5 million grant to offer a musculoskeletal care program in rural and remote parts of Australia. As a Professor of Allied Health and a physiotherapist, Trudy will lead the collaborative project involving University of
-
Tapping into our expertise to solve an escalating health challenge
Posted on:
A culture of collaboration is a key part of the Kolling Institute’s research impact, and just one example of this is a joint project to reduce the devastating impact of vascular disease linked to diabetes. The study has brought together research experts from endocrinology and cardiology to curb the number of lower limb amputations due
Category:
-
Kolling researchers make promising breakthrough with leukaemia study
Posted on:
While there has been a great deal of encouraging progress with many cancer treatments over the last decade, the prognosis for people with acute myeloid leukaemia remains dismal, with only 27 per cent of patients surviving more than five years after treatment. Lead researcher Dr Jenny Wang said we have seen a sharp rise in
Category:
